ELI LILLY AND COMPANY Other Receivables
ELI LILLY AND COMPANY (LLY) had Other Receivables of $1.66 billion as of 2022-12-31, per its 10-K filed 2023-02-22.
Discontinued › Notes
us-gaap:OtherReceivables · last filed 2023-02-22
- 2022-12-31: Other Receivables $1.66B.
- 2021-12-31: Other Receivables $1.45B.
- 2020-12-31: Other Receivables $1.05B.
- 2019-12-31: Other Receivables $994.20M.
| Period end | Other Receivables | Other Receivables as first filed |
|---|---|---|
| 2022-12-31 | $1.66B 10-K · filed 2023-02-22 | |
| 2021-12-31 | $1.45B 10-K · filed 2023-02-22 | |
| 2020-12-31 | $1.05B 10-K · filed 2022-02-23 | |
| 2019-12-31 | $994.20M 10-K · filed 2021-02-17 | |
| 2018-12-31 | $1.18B 10-K · filed 2020-02-19 | $958.40M 10-K · filed 2019-02-19 |
| 2017-12-31 | $689.50M 8-K · filed 2019-10-24 | $715.90M 10-K · filed 2018-02-20 |
| 2016-12-31 | $736.90M 10-K · filed 2018-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |